World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ANZCTR
Last refreshed on: 13 January 2020
Main ID:  ACTRN12607000050459
Date of registration: 16/01/2007
Prospective Registration: No
Primary sponsor: Sandie Bredemeyer
Public title: Chlorhexidine in preterm babies
Scientific title: Use of chlorhexidine as a topical antiseptic for the prevention of nosocomial sepsis in premature neonates < 29 weeks: a blinded randomised controlled trial
Date of first enrolment: 04/04/2005
Target sample size: 169
Recruitment status: Recruiting
URL:  https://anzctr.org.au/ACTRN12607000050459.aspx
Study type:  Interventional
Study design:  Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy;  
Phase: 
Countries of recruitment
Australia
Contacts
Name: Sandie Bredemeyer   
Address:  RPA Women and Babies Newborn Care Unit Missenden Rd Camperdown NSW 2050 Australia
Telephone: +61 2 95158923 / +61 2 93510505
Email: sbredemeyer@nursing.usyd.edu.au
Affiliation: 
Name: Sandie Bredemeyer   
Address:  RPA Women and Babies Newborn Care Unit Missenden Rd Camperdown NSW 2050 Australia
Telephone: +61 2 95158923 / +61 2 93510505
Email: sbredemeyer@nursing.usyd.edu.au
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Inborn infants < 29 weeks. Informed parental consent.
Exclusion criteria: Parental consent not given. Ex utero transfer, unlikely to survive major congenital anomaly.

Age minimum: Days
Age maximum: 29 Weeks
Gender: Both males and females
Health Condition(s) or Problem(s) studied
Nosocomial infection in preterm babies;
Nosocomial infection in preterm babies
Reproductive Health and Childbirth - Complications of newborn
Intervention(s)
Aqueous chlorhexidine 0.5% (intervention group) applied topically. The solution is applied prior to each invasive procedure for both control and intervention groups.
Primary Outcome(s)
Number of episodes of nosocomial infection in infants < 29 weeks[During stay in the neonatal intensive care unit (NICU)]
Skin integrity[Before and after application of topical antiseptic]
Secondary Outcome(s)
Developmental outcomes at 12 months corrected age[]
Mortality before discharge from NICU[]
Necrotizing enterocolitis (NEC) at discharge from NICU []
Omphalitis at discharge from NICU []
Osteomyelitis at discharge from NICU[]
Antibiotic days at discharge from NICU []
Length of ventilation at discharge from NICU[]
Length of stay in a tertiary centre[]
Episodes of antibiotic use at discharge from NICU []
Secondary ID(s)
Source(s) of Monetary Support
NSW Nurses Midwives Registration Board
Secondary Sponsor(s)
Ester Carman
Nick Evans
Shelley Reid
Ethics review
Status: Not approved
Approval date:
Contact:
Royal Prince Alfred Hospital - RPA Newborn Care Unit
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history